Through the analysis of seven retrospective cohort studies involving 5,066,681 patients who received GLP-1 RAs, the findings reported that colorectal cancer risk was significantly associated with the use of GLP-1 RAs. The gene discussed is GCG; the disease is colorectal cancer.